Phase I trial of afatinib and 3-weekly trastuzumab with optimal anti-diarrheal management in patients with HER2-positive metastatic cancer

ConclusionsDespite optimal management of diarrhea including treatment of grade I symptoms, it was not possible to treat the patients above a dose of 20  mg of afatinib daily in combination with 3-weekly trastuzumab. The MTD of afatinib in combination with the recommended 3-weekly dose of trastuzumab was 20 mg daily.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research